Indiana is currently home to 1258 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Central Preservation and Assessment Service to Optimize Donor Kidney Allocation
NCT06263023
Recruiting
This is a study to collect information to assess if transporting hard-to-place (HTP) donor kidneys to a central preservation and assessment facility with dedicated organ assessment capabilities increases allocation success to transplant hospitals.
Gender:
All
Ages:
Between 16 years and 75 years
Trial Updated:
04/23/2024
Locations: Indiana University Health, Indianapolis, Indiana
Conditions: Organ Preservation
Register for Updates
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
04/23/2024
Locations: Riley Hospital for Children, Indianapolis, Indiana
Conditions: Colitis, Ulcerative
Register for Updates
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
NCT06235099
Recruiting
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Indiana University Health Neuroscience Center, Indianapolis, Indiana
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
Register for Updates
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931
Recruiting
The primary objective of this study is to assess the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the composite endpoint of all-cause mortality (ACM) and total cardiovascular (CV) clinical events.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/23/2024
Locations: Research Site, Indianapolis, Indiana
Conditions: Transthyretin Amyloid Cardiomyopathy
Register for Updates
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
NCT06169124
Recruiting
This phase II trial tests how well darolutamide in combination with leuprolide acetate and exemestane works in treating patients with ovarian granulosa cell tumors that have come back after a period of improvement (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Leuprolide acetate is in a class of medications called gonadotropin-relea... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Ascension Saint Vincent Indianapolis Hospital, Indianapolis, Indiana
Conditions: Adult Ovarian Granulosa Cell Tumor
Register for Updates
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty
NCT06129539
Recruiting
The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52 weeks after the first Debio 4326 injection in pediatric participants receiving gonadotropin-releasing hormone agonist (GnRHa) therapy for central precocious puberty (CPP).
Gender:
All
Ages:
Between 5 years and 8 years
Trial Updated:
04/23/2024
Locations: Indiana University/Riley Hospital for Children, Indianapolis, Indiana
Conditions: Central Precocious Puberty
Register for Updates
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
NCT06109441
Recruiting
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase, and a Maintenance Phase. Eligible subjects will be enrolled to receive a SC loading dose of ALTB-268 followed by weekly doses of ALTB-268 for 12 weeks. Primary efficacy endpoint will be evaluated at week 12. Week 12 dosing will occur during the 40 wks Ma... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/23/2024
Locations: Gastro Health Partners Southern Indiana, New Albany, Indiana
Conditions: Ulcerative Colitis
Register for Updates
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079
Recruiting
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Velocity Clinical Research, Valparaiso, Indiana
Conditions: Obesity
Register for Updates
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073
Recruiting
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
04/23/2024
Locations: Riley Hospital for Children, Indianapolis, Indiana
Conditions: Crohn's Disease
Register for Updates
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398
Recruiting
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level < 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Urology of Indiana, Greenwood, Indiana
Conditions: Metastatic Castrate-sensitive Prostate Cancer
Register for Updates
Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
NCT05856331
Recruiting
Phase 2 study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD emphysema
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/23/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema
Register for Updates
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
NCT05828069
Recruiting
This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form... Read More
Gender:
All
Ages:
Between 180 days and 22 years
Trial Updated:
04/23/2024
Locations: Riley Hospital for Children, Indianapolis, Indiana
Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Register for Updates